Deploying AI safely and effectively — between GxP, the EU AI Act, and operational reality
Are you already using AI in GxP-relevant processes — or planning to?
Then you are not just introducing a new technology.
You are changing the organization, processes, and the working environment of your employees.
Artificial intelligence is transforming pharma, biotechnology, and medical technology. Processes become more efficient, data analyses more powerful, and decision support more precise. At the same time, new regulatory requirements are emerging — especially where AI has a direct impact on product quality, patient rights & safety, or data integrity.
Between innovation pressure, the EU AI Act, and GxP requirements, a new level of complexity is taking shape. Without a structured framework, this either leads to operational paralysis — or increased regulatory risk.
QFINITY supports you in introducing and operating AI systems in a compliant, risk-based, and value-creating way — practical and future-oriented.
AI in a GxP-regulated environment is more than just software
In regulated environments, we do not view AI as an isolated application, but as a subsystem of an overarching computerized system.
Regulatory and economic viability only emerges through the interaction of:
- AI models and algorithms
- IT systems, infrastructure, and interfaces
- Business processes and SOPs
- Data quality, IT and information security
- Clearly defined roles and governance structures
- Qualified personnel
- Structured development, change management, and operational processes and/or effective collaboration with suppliers
Only this holistic perspective provides a foundation for stability.
Isolated measures do not.
Leveraging opportunities — managing risks
AI unlocks significant potential, including:
- Efficiency gains in quality- and documentation-intensive processes
- Advanced data analytics and new insights
- Support across the entire product lifecycle
At the same time, specific risks arise, such as:
- Data dependency and data quality
- AI model behavior and the traceability of results and decisions
- Greater operational dynamics regarding changes in production use
- New requirements for infrastructure and monitoring
- … and many more
Regulatory expectations in the GxP context are of particular importance. AI systems that affect GxP-relevant processes are subject to the same requirements as established computerized systems—supplemented by additional regulatory expectations in the GxP context as well as horizontal regulation such as the EU AI Act.
Two regulatory perspectives — one integrated solution
The use of AI must be assessed from two different perspectives:
GxP risk assessment
Evaluation of impacts on patient rights/safety, product quality, and data integrity. Based on this, risk-based decisions are made on lifecycle activities and control measures.
Risk classification under the EU AI Act
Classification based on intended purpose and area of use—independent of the technical implementation. Certain applications are considered high-risk AI systems if they are classified accordingly.
These different frameworks can lead to different risk assessments.
QFINITY integrates both perspectives within a consistent governance and lifecycle architecture.
Practical experience from real-world AI use cases
We have been supporting AI implementations in regulated environments for several years, including:
- AI-assisted image analysis in clinical applications
- Visual inspections in pharmaceutical manufacturing
- Yield optimization in pharmaceutical production
- Generative AI applications in deviation management
- LLM-based support in pharmacovigilance
- Post-market surveillance in medical technology
The greater the impact on patients or product quality, the higher the requirements for governance, validation, and monitoring.
CSV is necessary — but not sufficient
Validation activities are a core component. Successful AI implementations additionally require:
- A clear definition of the intended purpose
- Appropriate, well-justified acceptance criteria
- A traceable selection of data, e.g., regarding training, validation, and test datasets
- Transparency of design and implementation decisions
- Controlled changes and continuous monitoring
In addition, the following are critical:
- Structured change management
- Clear roles and qualifications
- Ongoing development of the quality management system
- A robust understanding of data and IT security
- Aligned expectations between suppliers and the regulated user
Our service approach
QFINITY supports you across the entire lifecycle:
- Establishing organizational and structural foundations for compliant AI use
- Integrating AI systems into existing IT and process landscapes
- Supporting validation and qualification projects
- Developing risk-based control and monitoring concepts
- Supporting supplier evaluation, audit preparation, and compliance evidence
In addition, we use AI selectively to increase efficiency and quality within CSV itself.
QFINITY — your partner for AI in regulated environments
AI in the GxP environment requires more than technological integration.
It demands structural change and a new understanding of responsibility.
Our goal is to consistently combine regulatory assurance and innovation.
So that AI systems remain robust, audit-ready, and operationally stable over the long term—and the expected added value can actually be achieved beyond pilot applications.
The structural framing should be established before regulatory inconsistencies or operational roadblocks arise
Let’s assess together how your AI initiative can be implemented in a way that is both regulatorily sound and effective in practice.
👉 Talk to us.
